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Summary
Background Globally, an estimated 15·6 million people inject drugs. We aimed to investigate global variation in the 
age profile of people who inject drugs (PWID), identify country-level factors associated with age of PWID, and assess 
the association between injecting drug use (IDU) in young people and rates of injecting and sexual risk behaviours at 
the country level.
Methods We derived data from a previously published global systematic review done in April, 2016 (and updated in 
June, 2017) on the percentage of young PWID, duration of IDU, average age of PWID, average age at IDU initiation, 
and the percentage of PWID reporting sexual and injecting risk behaviours. We also derived national development 
indicators from World Bank data. We estimated the percentage of young PWID for each country, using a random-
effects meta-analysis (DerSimonian-Laird methodology) and generated pooled regional and global estimates for all 
indicators of IDU in young people. We used univariable and multivariable generalised linear models to test for 
associations between the age indicators and country urban population growth, youth unemployment percentage, the 
percentage of PWID who are female, the percentage of the general population aged 15–24 years, Gini coefficient, 
opioid substitution therapy coverage (per PWID per year), gross domestic product (GDP) per capita (US$1000), and 
sexual and injecting risk behaviours.
Findings In the original systematic review, data on age of PWID was reported in 741 studies across 93 countries. 
Globally, 25·3% (95% uncertainty interval [UI] 19·6–31·8) of PWID were aged 25 years or younger. The highest 
percentage of young PWID resided in eastern Europe (43·4%, 95% UI 39·4–47·4), and the lowest percentage resided 
in the Middle East and north Africa (6·9%, 5·1–8·8). At the country level, in multivariable analysis higher GDP was 
associated with longer median injecting duration (0·11 years per $1000 GDP increase, 95% CI 0·04–0·18; p=0·002), 
and older median age of PWID (0·13 years per $1000 increase, 0·06–0·20; p<0·0001). Urban population growth was 
associated with higher age at IDU initiation (1·40 years per annual percentage change, 0·41–2·40). No associations 
were identified between indicators of IDU in young people and youth unemployment, Gini coefficient, or opioid 
substitution therapy coverage provision at the country level. No associations were identified between injecting and 
sexual risk behaviours and age of PWID.
Interpretation Variation in the age profile of PWID was associated with GDP and urbanisation. Regions with the 
highest prevalence of young PWID (aged ≤25 years) had low coverage of interventions to prevent the spread of blood-
borne viruses. Data quality highlights the need for improvements in monitoring of PWID populations.
Funding Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research 
Council, Open Society Foundation, WHO, the Global Fund, UNAIDS, National Institute for Health Research Health 
Protection Research Unit for Evaluation of Interventions, Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Globally, an estimated 15·6 million people aged 15–64 years 
inject drugs (95% uncertainty interval [UI] 10·2–23·7).1 
Injecting drug use (IDU) is of high public health impor­
tance because of the associated elevated risks of overdose, 
drug dependence, and blood­borne virus trans mission.2 
Subsequently, IDU is an important contributor to the 
global burden of disease.3
The initiation of IDU among young people is of great 
concern. Younger age of onset of IDU is associated 
with overdose,4 faster progression to regular heroin 
use,5 and lower treatment uptake.6 Young people who 
inject drugs (PWID) have been found to be more likely 
to share needles and syringes7 and can be at high risk 
for engagement in sexual behaviour, facilitating the 
spread of blood­borne viruses.8 Preventing the uptake 
of IDU among young people presents an opportunity to 
reduce the spread of these viruses to new generations 
and consequently reduce the associated health­care 
burden.
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Epidemiological data on PWID shows wide between­
country variation in the age profile of PWID, with the 
proportion of young PWID ranging from 6·7% in 
Kyrgyzstan and Ghana to 71% in Turkey.1 To date, 
research on the correlates of IDU has largely focused 
on individual­level factors.9,10 Less is known about the 
national­level characteristics that might contribute to 
differences in the age profile of PWID.
Adolescent health faces challenges in the context of 
modern development. The largest proportion of young 
people (aged 15–24 years) reside in Africa, Asia, and 
Latin America;11 regions that comprise the highest 
numbers of low­income and middle­income countries 
(LMICs), and are typically undergoing urbanisation and 
its associated challenges.12 Addressing mental health 
needs of young people has been identified as a global 
challenge,13 but despite illicit drug use contri buting to the 
global burden of disease among young people,14 to what 
extent IDU varies among young people globally remains 
unknown.
By combining epidemiological data extracted during 
our previous global systematic review1 with national 
socioeconomic data from the World Bank,15,16 we aimed to 
assess between­country variation in PWID age indicators 
(percentage of PWID aged ≤25 years, median age of 
PWID, age of onset of injecting, and duration of IDU); 
the association between urban population growth, youth 
unemployment, per capita gross domestic product 
(GDP), Gini coefficient, opioid substitution therapy, and 
indicators of the age of the IDU population at the country 
level; and the association between youth IDU and rates 
of injecting and sexual risk behaviour at the country 
level.
Methods
Search strategy and selection criteria
Country­level data on the percentage of young PWID, 
duration of IDU, age of IDU onset, and average age 
of IDU were derived from our previous multistage 
global systematic review on the prevalence of IDU and 
characteristics of PWID.1 Full methods of our previous 
systematic review have been published elsewhere.1 
Briefly, we searched electronic peer­reviewed literature 
databases (MEDLINE, Embase, and PsycINFO), grey 
literature, online databases,17 and key documents pub­
lished by relevant international agencies and experts. 
Searches were restricted to studies published since 
Jan 1, 2008 (since the aim of the original study was to 
update estimates produced in 2008). Searches of the grey 
literature were done between April and June, 2016, and 
updated between May and June, 2017, and searches of 
peer­reviewed literature were done in June, 2017. Identified 
experts were emailed to request additional information. 
Search terms are provided in the published paper.1 No 
Research in context
Evidence before this study
In our 2017 systematic review, we identified wide country-level 
variation in the percentage of young people who inject drugs 
(PWID), which is a concern since young age of onset of injecting 
drug use (IDU) is associated with greater risk of overdose 
(regardless of duration of drug use), faster progression to regular 
heroin use, and lower uptake of drug treatment. To date, 
research into the predictors of the age profile of PWID has 
largely focused on individual-level factors such as childhood 
abuse and employment. Little is known about the country-level 
characteristics that might contribute to higher numbers of 
young PWID.
Added value of this study
In this study, we assessed IDU among younger people within 
the context of global development and identified substantial 
variation in the percentage of young PWID. The estimated 
global percentage of PWID aged 25 years or younger is 25·3% 
(around 3·9 million young PWID), but between countries 
these estimated percentages range from 5·1% to 53·8%. 
This study is the first to explore country-level factors that 
might contribute to this variation, and is the first to assess 
associations between IDU in young people and injecting and 
sexual risk behaviours at the country level. Lower gross 
domestic product (GDP) per capita was associated with a 
shorter median duration of injecting, and a lower median age 
of PWID. Lower urbanisation growth rates were associated 
with a younger age of onset of IDU. The results provide a 
compelling argument that growth and development might 
have implications for periods of epidemic drug use, and for 
necessary provision of measures to prevent the spread of 
blood-borne viruses.
Implications of all the available evidence
Assessment of the global variation in IDU among young people 
has identified countries in which youth IDU urgently needs to 
be addressed, with this group accounting for up to half of the 
PWID population in some countries. Many of the regions with 
the highest percentages of young PWID had the lowest 
provision of harm reduction to prevent the spread of HIV and 
hepatitis C. Nationally, GDP and urban population growth were 
associated with indicators of youth injecting and consequently, 
greater consideration of IDU within the context of development 
goals is warranted.
Figure 1: Flowchart of study inclusion criteria
Adapted from Degenhardt and colleagues.1 EMCDDA=European Monitoring 
Centre on Drugs and Drug Addiction. GSHR=HRI’s Global State of Harm 
Reduction. HBV=hepatitis B virus. HCV=hepatitis C virus. IDU=injecting drug use. 
PWID=people who inject drugs. UNODC WDR=UN Office on Drugs and Crime’s 
World Drug Report. 
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language restrictions were used, and non­English lan­
guages were read by the research team or via translation 
programs.
Screening and selection
Studies were screened on the basis of pre­specified 
decision rules and study quality assessment, with higher 
quality studies selected over lower quality studies.1 Initial 
title and abstract screening was done independently by 
one reviewer, with a random 10% of studies checked by a 
second person (LD, SL, or AP). Full­text review was done 
independently by two authors (LD, SL, or AP), with any 
discrepancies resolved by consensus or by a third 
reviewer (MH) for searches that yielded fewer than 
30 records; a consensus was reached in all instances. 
We extracted data at all levels reported in the study, 
including city, subnational, and country. Data were then 
checked for accuracy against the original source by one 
of three authors (LD, SL, or AP). The review was reported 
in accordance with PRISMA18 and GATHER19 guide­
lines,1 and the protocols were registered on PROSPERO, 
numbers CRD42016052858 and CRD42016052853.17,20 
The national dev elopment indicators were obtained 
from the World Bank Data Catalog.15
Data extraction
Full details of all outcomes are in the appendix (pp 2–4). 
Studies recorded the per centages of PWID (at time of 
study data collection) in different age categories for current 
injectors. To ensure our analysis focused on young people, 
to estimate the percentage of young PWID, we excluded 
data from studies in which the youngest age group 
included adults aged older than 25 years.21
We extracted data on median duration of IDU and 
average age of PWID at the time of study data collection 
where reported, and data on average age of IDU onset at 
time of study data collection, if directly reported.
For age of PWID and age of onset of IDU, we used a 
median (range) where available and a mean (range) 
where a median was not available but a mean was; 
hence, we refer to these as averages throughout, rather 
than specifically as means and medians. Duration of 
IDU is presented as a median (range).
To assess whether measures of youth IDU were asso­
ciated with sociodemographic and wealth indicators, we 
derived data on the following development indicators 
for 2015 from The World Bank Catalog and the UN:11,15,16 
GDP per capita (US$ thousand), youth unem ployment 
(proportion of labour force aged 15–24 years), urban 
population growth (annual percentage change in the 
popu lation residing in urban areas), Gini coefficient 
(measuring inequality on a scale from 0–100, whereby a 
lower score indicates higher equality), and the proportion 
of the general population aged 15–24 years.16 We obtained 
data from previous meta­analyses for measures of opioid 
substitution therapy coverage22 (per PWID per year) and 
the percentage of female PWID at the country level.23
We also estimated the percentage of PWID who 
had recently engaged in injecting risk behaviour (pre­
dominantly receptive needle sharing, typically in the past 
month) and the percentage of PWID who had recently 
engaged in sexual risk behaviour (predominantly no or 
inconsistent condom use with casual partner, typically 
within the past month).
Data analysis
All analyses were done using Stata (version 15.0), with 
the exception of mapping, which was done in Tableau.
We estimated the percentage of young PWID aged 
25 years and under for each country, pooled using a 
random­effects meta­analysis (DerSimonian­Laird meth­
od ology) via the Metaprop command in Stata 15.0. The 
number of people included in the young age group and 
the overall sample size for each study were specified, 
using the Freeman­Tukey double arcsine transformation 
to stabi lise the variances. We used the I² statistic to assess 
heterogeneity between studies for the percentage of 
young PWID, for each country.24
The tabulations for the average age of PWID, average 
age of onset of injecting, and average duration of injecting 
were produced by weighting each study according to 
sample size and creating a mean (range) for each country. 
The percentage of PWID who were young, and the 
median years of injecting among PWID, were mapped 
for each country.
Regional and global estimates for all indicators of 
youth IDU were pooled by weighting the size of the 
PWID population in the countries within each region.
We used generalised linear models to test for asso­
ciations using the percentage of young PWID (converted 
to a proportion and logit transformed: log[p/(1­p)]), 
average age of PWID, average age of onset of injecting, 
and median duration of injecting in the country as the 
dependent variables, and urban popu lation growth, 
youth unemployment, the percentage of PWID who 
were women, the percentage of the general population 
aged 15–24 years, Gini coefficient, opioid substitution 
therapy coverage (per PWID per year), and GDP per 
capita (US$ thousand) as independent variables. Ana­
lyses were done at the country level because our aim 
was to analyse the variation in the percentage of young 
PWID between countries, rather than between studies. 
All independent variables associated with the depen­
dent variables in the univariable analyses (p<0·05) were 
entered in multivariable analyses. This method was 
repeated using the percentage of PWID reporting 
injecting risk and the percentage of PWID reporting 
sexual risk behaviour (both logit transformed) as 
dependent variables. Median age, duration of injecting, 
age of onset of injecting, and the percentage of young 
PWID were modelled separately as the independent 
variables. Independent variables associated with the 
dependent variables (p<0·05) in the univariable ana­
lyses were entered in multivariable analyses. Estimates 
See Online for appendix
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lacking information on the origin of the source study 
were excluded. A conservative Bonferroni correction of 
0·008 (ie, 0·05/6) was used as the p value for the multi­
variable analyses to account for multiple hypothesis 
testing in the six multivariable models.
We used sensitivity analyses to investigate the effect 
of defining young PWID with different age cutoffs 
(appendix pp 1–3).
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all of the data in the study and had final 
responsibility for the decision to submit for publication.
Results
The systematic search1 yielded 55 671 studies, of which 
1147 studies met inclusion criteria (figure 1). Data on age 
of PWID was reported in 741 studies across 93 countries 
(appendix pp 5–46), accounting for 79% of the global 
population. All study variables and country­level I² values 
are shown in the appendix (pp 5–7).
Globally, 25·3% (95% UI 19·6–31·8) of PWID were 
young (aged ≤25 years), equating to approximately 
3·9 mil lion (3·1–5·0) young people. The average age of 
PWID was 32·5 years (range 18–55), and the average age 
of onset of IDU was 23·3 years (13–39). The weighted 
mean of the median durations of IDU was 9·7 years 
(1–25) across studies.
Large variations were identified in the estimated 
percentage of young PWID by region and by country 
(table 1; figure 2A). The highest percentage of young 
PWID resided in eastern Europe (43·4%, 95% UI 
39·4–47·4) and the lowest in the Middle East and north 
Africa (6·9%, 5·1–8·8). The shortest regional duration 
of IDU was estimated in sub­Saharan Africa (4·6 years, 
range 3–17), and the longest duration in North America 
(16·0 years, 4–21; table 1; figure 2B). The youngest 
median age of PWID in a region was estimated to be 
in eastern Europe (27·9 years, range 19–43) and the 
oldest was in North America (37·6 years, 28–55; table 1; 
figure 2C). The youngest age of IDU onset was esti­
mated to be in Australasia (19·1 years, range 17–20) and 
the oldest was in the Middle East and north Africa 
(28·9 years, range 20–29; table 1; figure 2D).
Higher country­level urban population growth was 
associated with increased age of IDU onset and a shorter 
duration of IDU in univariable analyses. However, 
this association was only maintained in multivariable 
analysis for age of IDU onset (tables 2, 3; figure 3A). No 
associations were identified between urban population 
growth and indicators of youth IDU in multivariable 
analysis.
Higher national youth unemployment was associated 
with lower age of IDU onset in univariable analyses, 
but this association was attenuated after adjustment 
(tables 2, 3; figure 3A). No asso ciations were identified 
between the level of youth unemployment and indicators 
of youth IDU in univariable and multivariable analyses.
Estimated number of PWID, n 
(95% UI)*
Young PWID, % 
(95% CI)
Average age of 
PWID, years (range)
Average age of 
onset of injecting, 
years (range)
Median duration 
of injecting, years 
(range)
Global 15 648 000 (10 219 000–23 737 500) 25·3% (19·6–31·8) 32·5 (18–55) 23·3 (13–39) 9·7 (1–25)
Eastern Europe
Overall 3 002000 (1 653 500–5 008 000) 43·4% (39·4–47·4) 27·9 (19–43) 19·4 (15–29) 8·7 (2–20)
Armenia 13 000 (9000–29 000) ·· 38·5 (34–43) ·· ··
Azerbaijan 43 500 (34 500–52 000) ·· 36·0 (33–40) 27·3 (25–29) 8·8 (5–12)
Belarus 40 500 (15 000–66 000) 20·1% (10·5–31·9) 30·8 (26–35) 19·0 (17–20) 10·9 (8–13)
Bosnia and Herzegovina ·· 16·6% (7·9–27·6) 31·0 (25–33) 15·3 (15–16) 15·0 (9–17)
Bulgaria 18 500 (15 000–22 500) ·· 29·4 (28–30) 19·0 (19–19) 9·0 (9–9)
Czech Republic 47 000 (44 500–49 000) ·· 27·5 (27–31) ·· ··
Estonia 8500 (6500–16 000) 35·4% (26·2–45·2) 27·6 (23–30) 19·6 (18–22) 8·1 (5–11)
Georgia 115 000 (13 000–217 000) 12·7% (9·5–16·3) 36·9 (32–40) 19·4 (18–26) 14·1 (5–20)
Hungary 4000 (2000–6000) 26·8% (21·7–32·3) 26·7 (23–33) 21·3 (20–22) 9·6 (8–11)
Latvia 14 000 (11 000–18 000) 28·2% (24·9–31·6) 28·6 (28–30) 19·4 (19–20) 9·1 (8–10)
Lithuania 5000 (2500–8000) 18·0% (14·4–22·1) 29·4 (29–30) 19·0 (19–19) 10·0 (10–10)
Moldova 12 000 (7500–16 500) 13·4% (6·5–22·3) 32·2 (27–36) 19·5 (17–21) 12·7 (10–15)
Poland ·· 37·5% (18·7–58·6) 27·8 (21–35) 18·0 (18–18) 14·4 (13–16)
Romania 81 500 (60 500–110 000) 31·8% (27·7–36·0) 28·7 (27–31) 18·5 (16–20) 9·8 (8·1–11)
Russia 1 881 000 (1 028 500–3 114 000) 52·1% (48·3–55·9) 26·2 (19–33) 19·4 (17–21) 7·6 (2–10)
Slovakia 20 000 (14 500–36 000) ·· 26·5 (25–29) ·· ··
Ukraine 319 500 (172 000–590 500) 19·8% (15·0–25·0) 32·1 (29–35) 18·5 (18–23) 12·2 (6–16)
(Table 1 continues on next page)
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Estimated number of PWID, n 
(95% UI)*
Young PWID, % 
(95% CI)
Average age of 
PWID, years (range)
Average age of 
onset of injecting, 
years (range)
Median duration 
of injecting, years 
(range)
(Continued from previous page)
Western Europe
Overall 1 009 500 (686 500–1 386 500) 14·1% (10·2–18·7) 34·0 (21–48) 20·5 (18–26) 10·7 (5–22)
Albania ·· ·· ·· ·· ··
Andorra ·· ·· ·· ·· ··
Austria 185 00 (12 500–24 500) ·· 32·0 (32–32) 19·0 (19–19) 13·0 (13–13)
Belgium 26 000 (18 500–37 000) 14·4% (11·3–17·8) 35·4 (34–37) 21·7 (21–22) 13·3 (13–14)
Croatia 6500 (5000–8500) 14·4% (7·8–22·6) 31·3 (26–37) 19·5 (18–25) 13·5 (5–19)
Denmark 16 500 (13 000–19 000) ·· 43·5 (37–45) 23·8 (18–25) 18·2 (18–19)
England 210 500 (196 500–225 000) 19·5% (16·4–22·8) 28·6 (22–36) ·· 10·0 (10–10)
Finland 17 000 (15 000–25 000) ·· ·· ·· ··
France 82 000 (66 500–97 000) ·· ·· ·· ··
Germany 131 500 (14 000–249 500) 6·6% (3·6–10·5) 35·8 (28–41) 21·4 (19–23) 13·9 (8–18)
Greece 5000 (4000–6000) 12·8% (6·6–20·7) 32·6 (27–36) 23·8 (21–24) 11·7 (8–12)
Iceland ·· ·· 33·0 (33–33) 20·0 (20–20) 7·0 (7–7)
Ireland 8500 (6500–10 500) 8·9% (6·1–12·4) 32·5 (30–33) ·· ··
Italy 341 500 (233 500–467 500) ·· 36·5 (29–46) 20·0 (20–20) 9·0 (9–9)
Luxembourg 2000 (1500–2500) ·· ·· ·· ··
Malta ·· ·· ·· ·· ··
Monaco ·· ·· ·· ·· ··
Montenegro ·· 39·0% (33·7–44·5) 27·0 (25–29) 23·0 (23–23) 6·0 (6–6)
Netherlands 3500 (2500–4500) ·· ·· ·· ··
North Macedonia ·· ·· 27·5 (21–36) ·· ··
Northern Ireland ·· ·· ·· ·· ··
Norway 8500 (7000–10 000) ·· 36·9 (33–38) 20·0 (20–20) 14·0 (14–14)
Portugal 16 000 (13 500–17 500) ·· 38·0 (38–38) ·· ··
San Marino ·· ·· ·· ·· ··
Scotland 16 000 (13 500–17 500) 12·1% (7·9–17·2) 34·5 (26–37) 21·4 (20–22) 11·5 (7–13)
Serbia 29 000 (24 000–34 500) 30·7% (15·7–48·2) 27·9 (23–31) 19·6 (18–20) 8·8 (5–11)
Slovenia 6000 (4000–7500) 10·8% (6·9–15·9) 33·0 (33–33) ·· ··
Spain 10 500 (3500–17 500) 20·5% (4·9–43·0) 35·7 (27–41) 21·0 (21–21) 11·2 (7–15)
Sweden 8000 (2000–38 500) ·· 37·1 (30–48) 20·8 (19–26) 21·0 (14–22)
Switzerland 13 500 (11 000–16 000) ·· 35·0 (35–35) ·· ··
Wales ·· 27·4% (24·2–30·9) 30·0 (30–30) ·· 9·0 (9–9)
East and southeast Asia
Overall 3 989 000 (3 041 000–4 955 000) 22·0% (16·5–28·0) 32·7 (21–53) 26·4 (13–39) 7·4 (1–25)
Brunei ·· ·· ·· ·· ··
Cambodia 10 500 (9500–22 500) ·· 25·5 (23–29) ·· ··
China 2 564 000 (1 964 000–3 164 000) 22·3% (17·2–27·8) 32·9 (26–53) 27·3 (24·5–36) 7·1 (1·5–25)
Hong Kong ·· ·· 49·0 (49–49) 32·0 (32–32) 17·0 (17–17)
Indonesia 190 500 (156 000–225 000) 14·1% (7·0–23·2) 29·4 (22–33) 20·2 (13–22) 7·1 (4–13)
Japan 368 500 (281 500–459 000) ·· ·· ·· ··
Laos ·· ·· 30·0 (30–30) ·· ··
Malaysia 281 500 (233 500–330 000) ·· 38·0 (37–39) 24·0 (24–24) 13·9 (13–15)
Mongolia ·· ·· ·· ·· ··
Myanmar 173 500 (115 500–235 000) 25·2% (21·3–29·2) 27·2 (24–33) 26·0 (22–31) 3·4 (1–11)
Philippines 25 500 (19 000–32 000) 44·3% (16·2–74·6) 25·3 (21–30) 18·5 (18–19) 6·8 (3–11)
South Korea ·· ·· 41·2 (39–42) 36·5 (29–39) 4·8 (3–10)
Singapore ·· ·· 43·0 (43–43) ·· ··
Taiwan ·· ·· 40·8 (37–45) 26·4 (26–27) 15·5 (14–18)
Thailand 51 500 (16 000–87 000) 9·7% (3·1–19·4) 32·2 (27–42) ·· ··
(Table 1 continues on next page)
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Estimated number of PWID, n 
(95% UI)*
Young PWID, % 
(95% CI)
Average age of 
PWID, years (range)
Average age of 
onset of injecting, 
years (range)
Median duration 
of injecting, years 
(range)
(Continued from previous page)
Timor Leste 500 (500–500) ·· ·· ·· ··
Vietnam 161 000 (123 000–200 500) 22·8% (15·6–30·8) 31·7 (22–38) 25·9 (21–32) 5·8 (4–8)
South Asia
Overall 1 023 500 (783 500–1 263 000) 26·4% (21·5–31·5) 30·3 (20–44) 25·2 (16–35) 5·7 (1–21)
Afghanistan 139 000 (88 000–190 500) 25·3% (19·8–31·1) 28·3 (21–32) 26·2 (24–28·5) 2·5 (1–4)
Bangladesh 68 500 (63 500–74 000) 28·7% (26·3–31·1) 32·6 (27–42) 26·5 (22–35) 6·0 (1–9)
Bhutan ·· ·· ·· ·· ··
India 197 000 (127 500–267 000) 42·8% (34·5–51·3) 29·4 (21–39) 22·0 (16–31) 7·2 (2–21)
Iran 158 000 (107 000–209 000) 14·9% (11·6–18·4) 32·7 (27–44) 24·3 (19–29) 8·2 (3–19)
Maldives 1500 (500–2500) 39·1% (33·4–45·0) 25·5 (25–26) 22·0 (22–22) 3·5 (3–4)
Nepal 35 000 (33 500–37 000) 27·2% (15·0–41·4) 24·2 (20–33) 20·7 (19–23) 5·2 (3–12)
Pakistan 423 000 (363 000–482 500) 22·9% (19·4–26·6) 30·5 (28–34) 26·9 (22–29) 5·1 (5–8)
Sri Lanka 500 (500–500) 8·6% (5·8–12·2) 40·0 (40–40) 26·0 (26–26) 11·0 (11–11)
Central Asia
Overall 281 500 (189 500–416 500) 7·0% (5·4–8·8) 32·5 (30–46) 24·8 (23–32) 5·7 (4·6–7)
Kazakhstan 112 500 (75 500–166 000) ·· 30·0 (30–30) 23·0 (23–23) 5·0 (5–5)
Kyrgyzstan 28 500 (19 000–42 000) 7·0% (5·4–8·8) 41·0 (36–46) 30·5 (28–32) 6·3 (5–7)
Tajikistan 235 000 (16 000–34 500) ·· 32·6 (31–38) 24·9 (24–26) 5·9 (4·6–7)
Turkmenistan ·· ·· ·· ·· ··
Uzbekistan 94 000 (63 000–140 000) ·· ·· ·· ··
Caribbean
Overall 79 500 (53 000–118 000) ·· NE (36–42) NE (20–24) NE (10–17)
The Bahamas ·· ·· ·· ·· ··
Bermuda ·· ·· ·· ·· ··
Dominican Republic ·· ·· ·· ·· ··
Haiti ·· ·· ·· ·· ··
Jamaica ·· ·· ·· ·· ··
Puerto Rico ·· ·· 40·5 (36–42) 21·2 (20–24) 12·9 (10–17)
Latin America
Overall 1 823 000 (1 392 000–2 380 000) ·· NE (18–37) 19·3 (17–21) 16·1 (3–18)
Argentina 80 500 (79 000–82 500) ·· ·· ·· ··
Bolivia ·· ·· ·· ·· ··
Brazil 962 000 (734 500–1 256 000) ·· ·· ·· ··
Chile 47 000 (36 000–61 500) ·· ·· ·· ··
Colombia ·· 53·8% (46·4–61·1) 21·6 (18–25) 20·0 (20–20) 3·0 (3–3)
Costa Rica ·· ·· ·· ·· ··
Ecuador ·· ·· ·· ·· ··
El Salvador ·· ·· ·· ·· ··
Guatemala ·· ·· ·· ·· ··
Guyana ·· ·· ·· ·· ··
Honduras ·· ·· ·· ·· ··
Mexico 150 500 (100 500–209 500) ·· ·· 19·3 (17–21) 16·1 (15–18)
Nicaragua ·· 29·3 (16·1–45·5) 30·0 (30–30) 18·0 (18–18) 6·0 (6–6)
Panama ·· ·· ·· ·· ··
Paraguay ·· ·· ·· ·· ··
Peru ·· ·· ·· ·· ··
Suriname ·· ·· ·· ·· ··
Uruguay 6500 (2000–9000) ·· ·· ·· ··
Venezuela ·· ·· ·· ·· ··
(Table 1 continues on next page)
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Estimated number of PWID, n 
(95% UI)*
Young PWID, % 
(95% CI)
Average age of 
PWID, years (range)
Average age of 
onset of injecting, 
years (range)
Median duration 
of injecting, years 
(range)
(Continued from previous page)
North America
Overall 2 557 000 (1 498 500–4 428 000) 13·3% (6·0–22·6) 37·6 (28–55) 22·3 (18–29) 16·0 (4–21)
Canada 308 000 (262 000–354 500) 33·5% (16·1–53·6) 36·9 (30–48) 21·9 (18–26) 14·3 (4–20)
USA 2 248 500 (1 236 500–4 074 000) 10·5% (4·6–18·3) 37·7 (28–55) 22·4 (19–29) 16·2 (5–21)
Pacific Island States and Territories
Overall 22 500 (15 000–33 500) ·· ·· ·· ··
American Samoa ·· ·· ·· ·· ··
Federated States of 
Micronesia
·· ·· ·· ·· ··
Fiji ·· ·· ·· ·· ··
French Polynesia ·· ·· ·· ·· ··
Guam ·· ·· ·· ·· ··
Kiribati ·· ·· ·· ·· ··
Marshall Islands ·· ·· ·· ·· ··
New Caledonia ·· ·· ·· ·· ··
Northern Mariana Islands ·· ·· ·· ·· ··
Palau ·· ·· ·· ·· ··
Papua New Guinea ·· ·· ·· ·· ··
Samoa ·· ·· ·· ·· ··
Solomon Islands ·· ·· ·· ·· ··
Tonga ·· ·· ·· ·· ··
Vanuatu ·· ·· ·· ·· ··
Australasia
Overall 115 500 (83 000–148 000) 22·5% (9·8–38·5) 35·6 (25–42) 19·1 (17–20) 15·4 (8–22)
Australia 93 000 (68 000–93 000) 22·5% (9·8–38·5) 34·7 (25–42) 19·1 (17–20) 15·4 (8–22)
New Zealand 22 500 (15 000–30 000) ·· 39·2 (33–42) ·· ··
Sub-Saharan Africa
Overall 1 378 000 (645 500–3 080 000) 20·7% (10·5–32·9) 29·4 (21–42) 28·2 (20–36) 4·6 (3–17)
Angola ·· ·· ·· ·· ··
Benin ·· 17·7% (14·5–21·2) 34·3 (32–35) 22·0 (22–22) 13·0 (13–13)
Burkina Faso ·· ·· ·· ·· ··
Burundi ·· ·· ·· ·· ··
Cameroon ·· ·· ·· ·· ··
Cape Verde ·· ·· ·· ·· ··
Chad ·· ·· ·· ·· ··
Democratic Republic of 
the Congo
3500 (0–158 000) 5·1% (1·7–11·5) 31·0 (31–31) ·· ··
Côte d’Ivoire 500 (500–1000) ·· 35·0 (35–35) ·· ··
Djibouti ·· ·· ·· ·· ··
Ethiopia ·· ·· ·· ·· ··
Gabon ·· ·· ·· ·· ··
The Gambia ·· ·· ·· ·· ··
Ghana ·· 6·7% (2·5–13·9) 42·0 (42–42) 27·0 (27–27) 10·0 (10–10)
Guinea ·· ·· ·· ·· ··
Kenya 30 500 (9000–52 000) 15·0% (11·4–18·9) 30·1 (26–32) 26·6 (23–33) 5·3 (4–6)
Liberia ·· ·· ·· ·· ··
Madagascar 15 500 (3000–79 500) 45·3% (10·8–82·6) 28·8 (21–31) ·· ··
Malawi ·· ·· ·· ·· ··
Mali ·· ·· ·· ·· ··
Mauritius 7000 (3500–14 000) 10·6% (8·0–13·6) 34·5 (31–38) 20·0 (20–20) 14·0 (11–17)
(Table 1 continues on next page)
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Higher GDP was positively associated with longer 
dura tion of IDU and the median age of PWID in 
both univariable analyses, and multivariable analyses 
(tables 2, 3; figure 3A). No associations were iden­
tified between the GDP and other indicators of youth 
IDU.
Estimated number of PWID, n 
(95% UI)*
Young PWID, % 
(95% CI)
Average age of 
PWID, years (range)
Average age of 
onset of injecting, 
years (range)
Median duration 
of injecting, years 
(range)
(Continued from previous page)
Mozambique 29 000 (0–59 000) ·· 22·0 (22–22) ·· ··
Namibia ·· ·· ·· ·· ··
Niger ·· ·· ·· ·· ··
Nigeria ·· 17·2% (6·9–31·0) 30·7 (30–40) 20·0 (20–20) 8·0 (8–8)
Rwanda 2000 (500–4500) ·· ·· ·· ··
Senegal ·· ·· ·· ·· ··
Seychelles 1500 (1000–2500) 28·0% (23·4–33·1) 28·0 (28–28) ·· ··
Sierra Leone 1500 (1000–1500) 8·1% (5·1–12·1) 29·0 (29–29) ·· ··
Somalia ·· ·· ·· ·· ··
South Africa 76 000 (21 500–268 000) ·· ·· ·· ··
eSwatini ·· ·· ·· ·· ··
Togo 2500 (500–19 500) 9·7% (6·4–13·8) 27·0 (27–27) ·· ··
Uganda ·· ·· ·· ·· ··
Tanzania 343 000 (200 000–486 000) 20·6% (10·6–32·7) 29·9 (27–35) 28·5 (20–36) 4·3 (3–9)
Zambia ·· ·· ·· ·· ··
Zimbabwe ·· ·· ·· ·· ··
Middle East and north Africa
Overall 349 500 (177 500–521 500) 6·9% (5·1–8·8) 33·5 (27–43) 28·9 (20–29) 10·0 (3–14)
Algeria ·· 36·8% (27·2–47·4) 30·0 (30–30) ·· ··
Bahrain ·· ·· ·· ·· ··
Cyprus 500 (500–1000) ·· 31·5 (27–32) 22·7 (20–23) 8·8 (7–9)
Egypt ·· ·· ·· ·· ··
Iraq ·· ·· 28·0 (28–28) ·· ··
Israel ·· ·· 43·0 (43–43) 29·0 (29–29) 14·0 (14–14)
Jordan ·· ·· ·· ·· ··
Kuwait ·· ·· ·· ·· ··
Lebanon ·· 17·3% (9·8–27·3) 29·5 (29–30) ·· ··
Libya 2000 (1000–3000) ·· 39·0 (39–39) ·· ··
Morocco 30 500 (15 500–45 500) 6·9% (5·1–8·8) 33·2 (31–39) 29·0 (29–29) 10·0 (10–10)
Occupied Palestinian 
territory
·· ·· 40·6 (39–43) 29·0 (29–29) 14·0 (14–14)
Oman ·· ·· ·· ·· ··
Qatar ·· ·· ·· ·· ··
Saudi Arabia ·· ·· 40·0 (40–40) ·· ··
Sudan ·· ·· ·· ·· ··
Syria ·· 24·4% (20·2–28·9) 32·0 (32–32) ·· ··
Tunisia ·· 14·6% (12·2–17·2) 34·6 (33–36) ·· ··
Turkey ·· ·· 27·2 (27–32) 23·2 (23–28) 4·0 (3–4)
United Arab Emirates ·· ·· ·· ·· ··
Yemen ·· ·· ·· ·· ··
For age of PWID and age of onset of IDU, we used a median (range) where available and a mean (range) where a median was not available but a mean was; hence, we refer 
to these as averages throughout. Data on injecting drug use were not available for Antigua and Barbuda, Barbados, Belize, Botswana, Central African Republic, Comoros, 
Cuba, Dominica, Equatorial Guinea, Eritrea, Greenland, Grenada, Guinea-Bissau, Lesotho, Liechtenstein, Mauritania, Namibia, Nauru, North Korea, Republic of the Congo, 
Saint Kitts and Nevis, Saint Lucia, São Tomé and Principe, Saint Vincent and the Grenadines, South Sudan, Trinidad and Tobago, and Tuvalu and thus these countries are not 
listed. Young PWID were defined as individuals aged younger than 25 years where possible; some studies used slightly different age groupings. Full details of all included 
studies are in the appendix (pp 5–46). ·· indicates no data available. NE=not estimable. PWID=people who inject drugs. UI=uncertainty interval. *Data obtained from 
Degenhardt and colleagues.1
Table 1: Age and injecting history parameters by country and region
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Gini coefficient was not associated with any of the 
indicators of youth IDU in the univariable analyses 
(tables 2, 3; figure 3A).
Higher opioid substitution therapy coverage was 
positively associated with a longer IDU duration in the 
univariable analysis, but this association was attenuated 
(Figure 2 continues on next page)
A
B
<15%
≥15 to <20%
≥20 to <25%
≥25 to <30%
≥30 to <40%
≥40 to <55%
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No evidence of injecting drug use
<6 years
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No estimate available
No evidence of injecting drug use
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Figure 2: Estimated percentage of young PWID (A), median duration of injecting drug use among PWID (B), average age of PWID population (C), and  
average age of onset of injecting among PWID (D), by country
PWID=people who inject drugs.
C
D
<20 years
≥20 to <22 years
≥22 to <25 years
≥25 to <27 years
≥27 to <30 years
≥30 years
No estimate available
No evidence of injecting drug use
≥21 to <28 years
≥28 to <32 years
≥32 to <36 years
≥36 to <40 years
≥40 to <44 years
No estimate available
No evidence of injecting drug use
Articles
e87 www.thelancet.com/lancetgh   Vol 8   January 2020
in the multivariable model (tables 2, 3; figure 3A). No 
associations were identified between opioid substi­
tution therapy coverage and other indicators of youth 
IDU. Sensitivity analyses of defining young PWID in 
different ways (appendix p 49) produced similar results 
to analyses seen in table 2.
Associations between percentage of young PWID, 
duration of IDU, age of IDU onset, and average age of 
IDU with injecting risk and sexual risk behaviours are 
shown in table 4 and figure 3B. An association was 
identified between older age of onset of injecting 
and increased injecting risk behaviours at the country 
level, but when entered into the multivariable analysis 
this association was not maintained owing to the 
strict p value used to account for multiple testing. No 
further associations were identified between indicators 
of youth IDU and injecting risk behaviours, and no 
associations were observed in univariable and multi­
variable analyses of the relationship to sexual risk 
behaviour (figure 3B).
Discussion
This study identified marked between­country variation 
in the percentage of PWID aged 25 years or younger; 
the global estimate is 25·3% (equivalent to approxi­
mately 3·9 million people), but between countries these 
percentages ranged from 7·0% to 50·8%. Half of the 
estimated PWID population in Latin America are aged 
25 years or younger (although only two countries pro­
vided data), and around a quarter of the IDU population 
was aged 25 years or younger in South Asia, eastern 
Europe, east and southeast Asia, North America, and 
Australasia. This study is the first to investigate country­
level factors underlying this variation, and the first to 
assess associations between youth IDU and population 
injecting and sexual risk behaviours. Lower GDP is 
associated with a shorter median duration of injecting, 
and with lower median age of the IDU population. Urban 
population growth is associated with a higher age of onset 
of IDU and, before adjustment, is associated with a 
shorter duration of IDU. No associations were observed 
Duration of injecting Percentage of PWID who are young
Univariable analysis (n=68) Multivariable analysis (n=53) Univariable analysis (n=60) Multivariable analysis 
(n=NA)
n Coefficient 
(95% CI)
p value Coefficient 
(95% CI)
p value n Coefficient 
(95% CI)
p value Coefficient 
(95% CI)
p value
Urban population growth 66 –1·25 (–1·86 to –0·63) 0·0001 –1·06 (–2·05 to –0·07) 0·036 60 –0·04 (–0·15 to 0·07) 0·486 ·· ··
Youth unemployment 66 0·06 (–0·02 to 0·14) 0·165 ·· ·· 59 0·00 (–0·01 to 0·02) 0·957 ·· ··
GDP (per US$1000 increase) 65 0·12 (0·07 to 0·17) <0·0001 0·11 (0·04 to 0·18) 0·002 59 –0·01 (–0·02 to 0·01) 0·329 ·· ··
Gini coefficient (per score increase) 65 –0·11 (–0·28 to 0·06) 0·206 ·· ·· 59 0·00 (–0·03 to 0·04) 0·881 ·· ··
Opioid substitution therapy coverage 
(per % increase in coverage)
55 0·06 (0·03 to 0·09) 0·001 0·02 (–0·02 to 0·05) 0·320 51 –0·01 (–0·01 to 0·00) 0·121 ·· ··
Percentage of PWID who are women 63 0·14 (0·05 to 0·24) 0·004 –0·01 (–0·13 to 0·12) 0·914 53 0·00 (–0·02 to 0·02) 0·843 ·· ··
Proportion of the general population 
aged 15–24 years
64 –0·59 (–0·86 to –0·31) <0·0001 0·02 (–0·40 to 0·55) 0·928 57 –0·01 (–0·06 to 0·06) 0·704 ·· ··
n refers to number of countries. The percentage of PWID who are young variable was logit transformed. GDP=gross domestic product. NA=not applicable. PWID=people who inject drugs.
Table 2: Country-level linear regression analyses of the predictors of duration of injecting among PWID and the age profile of PWID (logit transformed)
Average age of PWID Average age of onset of injecting
Univariable analysis (n=94) Multivariable analysis (n=79) Univariable analysis (n=66) Multivariable analysis (n=61)
n Coefficient (95% CI) p value Coefficient (95% CI) p value n Coefficient (95% CI) p value Coefficient (95% CI) p value
Urban population growth 92 –0·52 (–1·18 to 0·15) 0·129 ·· ·· 64 1·20 (0·62 to 1·78) 0·0001 1·40 (0·41 to 2·40) 0·007
Youth unemployment 91 –0·01 (–0·09 to 0·08) 0·887 ·· ·· 64 –0·09 (-0·16 to –0·01) 0·032 –0·05 (–0·14 to 0·04) 0·257
GDP (per US$1000 increase) 89 0·12 (0·07 to 0·17) <0·0001 0·13 (0·06 to 0·20) 0·0004 63 –0·01 (–0·07 to 0·04) 0·631 ·· ··
Gini coefficient (per score increase) 87 –0·06 (–0·23 to 0·11) 0·496 ·· ·· 63 0·05 (–0·12 to 0·22) 0·539 ·· ··
Opioid substitution therapy coverage 
(per % increase in coverage)
76 0·03 (–0·00 to 0·06) 0·078 ·· ·· 54 –0·02 (–0·06 to 0·01) 0·154 ·· ··
Percentage of PWID who are women 83 0·06 (–0·05 to 0·17) 0·276 –0·07 (–0·22 to 0·07) 0·293 63 –0·13 (–0·22 to –0·04) 0·005 –0·14 (–0·26 to -0·02) 0·019
Proportion of the general population 
aged 15–24 years
90 –0·32 (–0·63 to 0·02) 0·038 –0·06 (–0·44 to 0·31) 0·731 64 0·36 (0·09 to 0·64) 0·011 –0·45 (-0·96 to 0·06) 0·082
n refers to number of countries. For age of PWID and age of onset of IDU, we used a median (range) where available and a mean (range) where a median was not available but a mean was; hence, we refer to these as 
averages throughout.  GDP=gross domestic product. PWID=people who inject drugs.
Table 3: Country-level linear regression analyses of the predictors of the average age of PWID and average age of onset of injecting
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between indicators of youth IDU and country­level youth 
unemployment, Gini coefficient, or provision of opioid 
substitution therapy. Similarly, no indicators of youth 
IDU were associated with country­level injecting and 
sexual risk behaviours.
The observed variation in the age profile of PWID is 
plausibly driven by country­level factors, which warrants 
consideration of the association between development 
and IDU. From the results of this study, we hypothesise 
that countries with lower GDPs are likely to have a lower 
median age of PWID and shorter duration of IDU, and 
countries with increased urban population growth are 
likely to have IDU initiation among older age groups 
(shorter duration of IDU, but higher age of IDU onset). 
A projected 68% of the global population will reside in 
urban areas by 2050, with the majority of this growth 
expected to be driven by LMICs.25 Whether such changes 
in living and working condi tions might unintentionally 
result in environments that facilitate IDU requires 
consideration; these changing working and living 
conditions might represent key factors for prioritisation 
to optimise the Sustainable Development Goals26 for 
improved mental health.
Several regions with the highest prevalence of PWID 
aged 25 years or younger also have low coverage of 
interventions to prevent the spread of blood­borne 
Figure 3: Country-level predictors of indicators of youth injecting drug use (A) and the association between injecting and sexual risk variables and age and injecting history (B)
The variables on the percentage of PWID with injecting risk and sexual risk were logit transformed. Rsq gives the R² value that is proportional to how much of the variability in the dependent variable 
(eg, duration of injecting) is explained by the independent variable (eg, GDP). GDP=gross domestic product. OST=opioid substitution therapy. *p<0·001. †p<0·05.
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viruses. In a previous review of global coverage of opioid 
substitution therapy and needle and syringe pro­
grammes, coverage was found to be low in eastern 
Europe, east and southeast Asia, and North America.22 
The percentage of young PWID is high in Russia 
(>50% of the PWID population aged ≤25 years) and 
the Philippines—countries in which coverage of opioid 
substitution therapy and needle and syringe programmes 
is low,22 and punitive drug policies create barriers to 
harm reduction measures.27,28 Although our findings 
indicate that the age profile of PWID is not associated 
with country­level sexual and injecting risk behaviours 
(in contrast to previous research of indi vidual­level 
risk7,8) and no evidence indicated that country­level drug 
policy is driving variation in PWID age, young PWID 
in countries with low coverage of opioid substitution 
therapy and needle and syringe programmes will be 
exposed to greater risk of contracting blood­borne viruses 
than young PWID in countries with high coverage 
because of poor access to harm reduction measures. To 
prevent the epidemic spread of blood­borne viruses 
among new generations of PWID in countries with a 
high proportion of young PWID, increasing the public 
health burden, urgent upscaling of blood­borne viruses 
prevention coverage is needed in several countries. 
Outreach interventions might be especially effective for 
engaging young people with interventions to prevent 
the spread of blood­borne viruses.29
Our study also identified a number of countries with 
a concerning paucity of data on the age structure of 
populations of PWID. The countries with data available 
account for 79% of the global population. However, 
the highest proportion of countries with no data available 
were in sub­Saharan Africa (65%), the Caribbean (83%), 
Latin America (84%), and the Pacific Island States and 
Territories (100%). Notably, regions with the least available 
data fit the GDP and urbanisation profile identified in the 
present analyses as being associated with risk for young 
PWID, and for recent onset of IDU (shorter duration of 
IDU and higher age of onset). To monitor these areas, we 
reiterate calls for improved data transparency associated 
with IDU and increased epidemiological data investment 
in areas affected by problematic drug use.30
The results of this review and analysis must be con­
sidered in the light of several limitations. Heterogeneity 
was high between studies with regard to the age range 
used to define young PWID (appendix pp 5–7), with 
49 different age range categories identified. To ensure 
the results reflect the period of adolescence, we excluded 
any studies that included participants aged 26 and 
older as their youngest age group from the analyses of the 
proportion of young PWID, but it is plausible that this 
heterogeneity contributed to the null results observed for 
the percentage of young PWID. Excluding studies that 
included individuals aged 26 and older as the youngest 
PWID category reduced study power, although sensitivity 
analyses in which the exclusion age was increased to 
30 years and older yielded no substantive differences in 
results (appendix pp 48–49). All sensitivity analyses are 
reported in the appendix (pp 47–49).
The original systematic review1 included grey 
literature where available, which should mitigate the 
effect of publication bias. We have interpreted dura­
tion of IDU as a marker of the age of the injecting 
population (with the rationale that shorter duration 
will represent a younger population). However, the 
median duration and popu lation age estimated in this 
study might be biased, and the PWID within the 
studies included in the review will not necessarily be 
representative of those in the overall population, since 
populations captured in certain study types (eg, opioid 
substitution therapy centres) might be older than the 
Percentage of PWID with injecting risk Percentage of PWID with sex risk
Univariable analysis (n=70) Multivariable analysis (n=51) Univariable analysis (n=59) Multivariable analysis (n=NA)
n Coefficient (95% CI) p value Coefficient (95% CI) p value n Coefficient (95% CI) p value Coefficient (95% CI) p value
Average age 70 0·01 (–0·05 to 0·06) 0·811 ·· ·· 58 –0·00 (–0·07 to 0·06) 0·919 ·· ··
Duration of injecting 56 –0·03 (–0·09 to 0·02) 0·237 ·· ·· 48 –0·04 (–0·13 to 0·05) 0·410 ·· ··
Average age of onset of injecting 56 0·06 (0·01 to 0·12) 0·030 0·06 (0·01 to 0·12) 0·030 47 0·04 (–0·05 to 0·13) 0·414 ·· ··
Percentage of young PWID 55 0·82 (–1·06 to 2·70) 0·384 ·· ·· 46 0·76 (-1·62 to 3·14) 0·523 ·· ··
Urban population growth 69 0·05 (–0·09 to 0·20) 0·470 ·· ·· 57 –0·02 (–0·20 to 0·16) 0·855 ·· ··
Youth unemployment 68 –0·00 (–0·02 to 0·02) 0·990 ·· ·· 56 0·01 (–0·02 to 0·03) 0·647 ·· ··
GDP (per US$1000 increase) 66 0·00 (–0·01 to 0·02) 0·686 ·· ·· 55 0·00 (–0·02 to 0·02) 0·833 ·· ··
Gini coefficient (per score increase) 67 0·01 (–0·03 to 0·05) 0·594 ·· ·· 55 –0·01 (–0·07 to 0·04) 0·586 ·· ··
Opioid substitution therapy coverage 
(per % increase in coverage)
58 0·00 (–0·01 to 0·01) 0·652 ·· ·· 47 –0·00 (–0·01 to 0·01) 0·691 ·· ··
Percentage of PWID who are women 68 –0·01 (–0·03 to 0·01) 0·341 ·· ·· 56 0·00 (–0·03 to 0·03) 0·960 ·· ··
Proportion of the general population 
aged 15–24 years
70 0·00 (–0·07 to 0·06) 0·886 ·· ·· 58 0·02 (–0·06 to 0·11) 0·578 ·· ··
n refers to number of countries. Injecting risk and sexual risk variables were logit transformed. GDP=gross domestic product. NA=not applicable. PWID=people who inject drugs.
Table 4: Country-level linear regression analyses of the associations between injecting and sex risk variables and age and injecting history
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rest of the population of PWID. Lower median age of 
PWID populations will plausibly reflect mortality or 
cessation of IDU rather than bias. Further research 
assessing the factors that affect the duration of IDU in 
LMICs is needed to clarify these results.
In our analyses, we were unable to account for hetero­
geneity at the study level (with the exception of sample 
size weighting) for injecting duration, median age of 
PWID, and age at onset of injecting, and were unable to 
account for heterogeneity at the country level for all 
indicators of youth IDU. Hetero geneity at the study level 
was assessed for the percentage of young PWID; only 
two of 28 studies had an I² value of less than 85%. The 
use of national World Bank indicators in the analysis 
resulted in the decision to analyse the data at the country 
level rather than using individual studies as the unit of 
analysis, which subsequently reduced the study power.
Although our systematic review was completed in 2017,1 
much of the collected data were older (median publication 
year 2012). Consequently, the included World Bank and 
UN figures are only approximations for country­level 
factors at the time the studies were done. The greatest 
limitation of our study was that data were missing for 
many countries; in some regions, no countries contributed 
data towards regional estimates on youth injecting.
Substantial global variation exists in the age profile of 
populations of PWID. Young people comprise a large 
percentage of PWID in several LMICs that have poor 
coverage of measures to prevent the spread of blood­
borne viruses. Such measures are necessary to limit the 
burden of disease arising from IDU. Without scale­up, 
the risk of viruses spreading rapidly through new 
generations in LMICs is high.
Lower GDP and increase in urbanisation are associated 
with recent uptake of IDU (shorter duration and older 
age of onset) in the population, with lower GDP countries 
likely to have younger populations of PWID. Urbanisation 
might be linked to recent uptake of IDU among older 
individuals. A better understanding of the origins of 
these large cross­country differences and the implications 
for health could be used to improve global development 
policy.
To increase awareness of emerging trends in drug use 
among young people, and to respond accordingly to 
prevent epidemic IDU harms, we reiterate calls for 
improved data transparency and increased epidemiolo­
gical monitoring investment in areas affected by 
problematic drug use.
Contributors
LD, SL, MH, AP, JG, PV, ML, and JL conceptualised and designed the 
original systematic review. ML, LAH, LD, SL, and AP conceptualised 
and designed the present study. All authors made substantial 
contributions to the acquisition of data. LD, SL, ML, LAH, AT, JL, AP, 
and JG contributed to the study methods and analysis plan. AT did the 
analysis and generated the estimates. SC and JL produced figures. 
LAH, ML, and AT contributed to the interpretation of data for the 
manuscript. LAH drafted the first draft of the manuscript. All authors 
contributed to revising the manuscript critically for important 
intellectual content.
Declaration of interests
LAH reports grants from the Australian Government and Wellcome 
Trust during the conduct of the study. SL has received investigator­
initiated untied educational grants from Indivior. AP reports grants from 
the WHO, Global Fund, UNAIDS, and the Australian Government 
Department of Health during the conduct of the study, and has received 
investigator­initiated untied educational grants from Mundipharma and 
Seqirus. LD reports investigator­initiated untied educational grants for 
studies of opioid medications in Australia from Indivior, Mundipharma, 
and Seqirus. MH reports personal fees from MSD and Gilead Sciences, 
outside the submitted work. JG is a consultant and advisor for and has 
received research grants from AbbVie, Cepheid, Gilead Sciences, 
and MSD. All other authors declare no competing interests.
Acknowledgments
This study was partly funded by the Australian National Drug and 
Alcohol Research Centre (University of New South Wales). LAH is 
supported by a Sir Henry Wellcome Postdoctoral Fellowship from the 
Wellcome Trust and an Australian National Health and Medical 
Research Council (NHMRC) Senior Principal Research Fellowship. 
AP is supported by an NHMRC Early Career Fellowship. 
JL acknowledges funding from the Bill & Melinda Gates Foundation. 
The Kirby Institute is funded by the Australian Government 
Department of Health and Ageing. The views expressed in this 
publication are those of the authors and do not necessarily represent the 
position of the Australian Government. JG is supported by an NHMRC 
Career Development Fellowship. JS acknowledges funding from a PhD 
scholarship from the Engineering and Physical Sciences Research 
Council. AT has received PhD funding from the National Institute for 
Health Research (NIHR). MH and PV acknowledge support from NIHR 
Health Protection Research Unit in Evaluation of Interventions 
(HPRU EI) at the University of Bristol. MH is an NIHR senior 
investigator and acknowledges NIHR School of Public Health Research 
and the NIHR HPRU EI. PV acknowledges support from the NIHR 
HPRU in Blood Borne and Sexually Transmitted Infections at 
University College London and National Institute for Drug Abuse (grant 
number R01 DA037773–01A1). We thank the research assistants who 
assisted with searches for and extraction of data from the eligible papers 
in this review: Griselda Buckland and Harriet Townsend (National Drug 
and Alcohol Research Centre, University of New South Wales), and 
Diana Sergiienko (Ukrainian Institute of Public Health Policy). We also 
thank the individuals who provided encouragement and support in 
various ways throughout the conduct of this study, including circulating 
requests for data, provision of in­country contacts and assistance with 
locating data: Annette Verster, Vladimir Poznyak (WHO), Andre Noor, 
Eleni Kalamara (European Monitoring Centre for Drugs and Drug 
Addiction), Jinkou Zhao (the Global Fund), Keith Sabin (UNAIDS), 
Catherine Cook, (Harm Reduction International), and Riku Lehtovuori, 
and Gilberto Gerra (UN Office on Drugs and Crime). Assistance in 
sourcing and verifying data was provided by many individuals from 
government, non­government, and research organisations around the 
world, for which we are thankful.
Editorial note: the Lancet Group takes a neutral position with respect to 
territorial claims in published maps and institutional affiliations.
References
1 Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of 
injecting drug use and sociodemographic characteristics and 
prevalence of HIV, HBV, and HCV in people who inject drugs: 
a multistage systematic review. Lancet Glob Health 2017; 5: e1192–207.
2 Strang J, Bearn J, Farrell M, et al. Route of drug use and its 
implications for drug effect, risk of dependence and health 
consequences. Drug Alcohol Rev 1998; 17: 197–211.
3 Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden 
of disease attributable to injecting drug use as a risk factor for HIV, 
hepatitis C, and hepatitis B: findings from the Global Burden of 
Disease Study 2013. Lancet Infect Dis 2016; 16: 1385–98.
4 Lynskey MT, Hall W. Cohort trends in age of initiation to heroin 
use. Drug Alcohol Rev 1998; 17: 289–97.
5 Woodcock EA, Lundahl LH, Stoltman JJK, Greenwald MK. 
Progression to regular heroin use: examination of patterns, 
predictors, and consequences. Addict Behav 2015; 45: 287–93.
Articles
e91 www.thelancet.com/lancetgh   Vol 8   January 2020
6 Miller CL, Strathdee SA, Li K, Kerr T, Wood E. A longitudinal 
investigation into excess risk for blood­borne infection among 
young injection drug users (IUDs). Am J Drug Alcohol Abuse 2007; 
33: 527–36.
7 Armstrong G, Nuken A, Medhi GK, et al. Injecting drug use in 
Manipur and Nagaland, Northeast India: injecting and sexual risk 
behaviours across age groups. Harm Reduct J 2014; 11: 27.
8 Folch C, Casabona J, Brugal MT, et al. Sexually transmitted 
infections and sexual practices among injecting drug users in harm 
reduction centers in Catalonia. Eur Addict Res 2011; 17: 271–78.
9 Barker B, Kerr T, Dong H, Wood E, DeBeck K. History of being in 
government care associated with younger age at injection initiation 
among a cohort of street­involved youth. Drug Alcohol Rev 2017; 
36: 639–42.
10 Richardson L, DeBeck K, Feng C, Kerr T, Wood E. Employment and 
risk of injection drug use initiation among street involved youth in 
Canadian setting. Prev Med 2014; 66: 56–59.
11 UN Department of Economic and Social Affairs Population 
Division. World population prospects. Key findings and advances 
table. 2017 revision. United Nations Department of Economic and 
Social Affairs Population Division. https://reliefweb.int/sites/
reliefweb.int/files/resources/WPP2017_KeyFindings.pdf (accessed 
Oct 24, 2019).
12 Blum RW, Bastos FI, Kabiru CW, Le LC. Adolescent health in the 
21st century. Lancet 2012; 379: 1567–68.
13 Patel V, Flisher AJ, Hetrick S, McGorry P. Mental health of young 
people: a global public­health challenge. Lancet 2007; 369: 1302–13.
14 Gore FM, Bloem PJN, Patton GC, et al. Global burden of disease in 
young people aged 10–24 years: a systematic analysis. Lancet 2011; 
377: 2093–102.
15 The World Bank. World Development Indicators. 2017. 
https://datacatalog.worldbank.org/dataset/world­development­
indicators [(accessed July 26, 2017).
16 The World Bank. The atlas of social protection: indicators of 
resilience and equity. 2018. https://datacatalog.worldbank.org/
dataset/atlas­social­protection­indicators­resilience­and­equity 
(accessed March 27, 2018).
17 Morris MD, Shiboski S, Bruneau J, et al. Geographic differences in 
temporal incidence trends of hepatitis C virus infection among people 
who inject drugs: the InC3 collaboration. Clin Infect Dis 2017; 
64: 860–69.
18 Blach S, Zeuzem S, Manns M, et al. Global prevalence and 
genotype distribution of hepatitis C virus infection in 2015: 
a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161–76.
19 Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of 
hepatitis B and hepatitis C in people who inject drugs: results of 
systematic reviews. Lancet 2011; 378: 571–83.
20 Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection 
epidemiology among people who inject drugs in Europe: 
a systematic review of data for scaling up treatment and prevention. 
PLoS One 2014; 9: e103345.
21 Sawyer SM, Azzopardi PS, Wickremarathne D, Patton GC. The age 
of adolescence. Lancet Child Adolesc Health 2018; 2: 223–28.
22 Larney S, Peacock A, Leung J, et al. Global, regional, and country­level 
coverage of interventions to prevent and manage HIV and hepatitis C 
among people who inject drugs: a systematic review. 
Lancet Glob Health 2017; 5: e1208–20.
23 Leung J, Peacock A, Colledge S, et al. A global meta­analysis of the 
prevalence of HIV, hepatitis C virus, and hepatitis B virus among 
people who inject drugs–do gender­based differences vary by 
country­level indicators? J Infect Dis 2019; 220: 78–90.
24 Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for 
systematic reviews of interventions, 2nd edn. Chichester: 
John Wiley & Sons, 2019.
25 UN Department of Economic and Social Affairs Population 
Division. World urbanization prospects. The 2018 revision. 
United Nations Department of Economic and Social Affairs 
Population Division, 2018. https://population.un.org/wup/
Publications/Files/WUP2018­Report.pdf (accessed Oct 24, 2019).
26 Lund C, Brooke­Sumner C, Baingana F, et al. Social determinants 
of mental disorders and the Sustainable Development Goals: 
a systematic review of reviews. Lancet Psychiatry 2018; 5: 357–69.
27 Chapman AR, Babor TF. Duterte’s war on drugs and the silence of 
the addiction science community. J Stud Alcohol Drugs 2017; 
78: 491–93.
28 Kazatchkine M. Russia’s ban on methadone for drug users in 
Crimea will worsen the HIV/AIDS epidemic and risk public health. 
BMJ 2014; 348: g3118.
29 Denno DM, Chandra­Mouli V, Osman M. Reaching youth with 
out­of­facility HIV and reproductive health services: a systematic 
review. J Adolesc Health 2012; 51: 106–21.
30 Hickman M, Larney S, Peacock A, Jones H, Grebely J, 
Degenhardt L. Competing global statistics on prevalence of 
injecting drug use: why does it matter and what can be done? 
Addiction 2018; 113: 1768–74.
